Neil H. Segal, MD, PhD, discusses the current role of immunotherapy in colorectal cancer and the work being done to define its role in earlier-line settings and among patients with microsatellite stable disease.
The approval of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer is generating hopes that similar strategies also may be effective against HER2-expressing gastric and colorectal cancers, according to a panel of experts in gastrointestinal malignancies.
James J. Harding, MD, discusses the evolving treatment landscape in frontline hepatocellular carcinoma and ongoing trials that may revolutionize the space.
The combination of nivolumab and the investigational CSF-1R inhibitor cabiralizumab with and without chemotherapy did not improve progression-free survival compared with chemotherapy alone in patients with advanced pancreatic cancer, missing the primary endpoint of a phase II trial (NCT03336216).
Ghassan K. Abou-Alfa, MD, discusses the treatment options that have emerged in advanced hepatocellular carcinoma and the work being done to determine optimal sequencing strategies.
David H. Ilson, MD, PhD, discusses the treatment landscape of advanced gastric cancer and the research being done to define a role for novel agents in this space.
Eileen O’Reilly, MD, reflects on the treatment advances that are expanding the pancreatic cancer paradigm.
Yelena Janjigian, MD, highlights key updates from the 2020 Gastrointestinal Cancers Symposium and explained the impact that new data will have on clinical practice.
Diane Simeone, MD, discusses recent data on neoadjuvant and adjuvant therapy for patients with locally advanced or resectable pancreatic cancer, and questions surrounding germline testing for earlier identification of this disease.
Investigators will challenge therapeutic convention by testing a PARP inhibitor instead of an IDH-targeted therapy in patients with metastatic IDH1/2-mutated glioma, cholangiocarcinoma, and other solid tumors that are refractory to standard treatment.